Welcome to our dedicated page for Heartbeam SEC filings (Ticker: BEAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want to see how HeartBeam鈥檚 credit card鈥搒ized ECG device moves from FDA submission to commercial revenue? Our SEC filings hub puts every disclosure at your fingertips. From the latest HeartBeam insider trading Form 4 transactions to the quarterly earnings report 10-Q filing that details R&D spend on Vector ECG technology, each document is delivered seconds after it hits EDGAR.
AI-powered summaries break down complex medical terminology, so understanding HeartBeam SEC documents with AI feels as direct as reading a headline. Need real-time alerts? HeartBeam Form 4 insider transactions real-time feed flags executive stock transactions Form 4 the moment they鈥檙e posted. Looking for revenue guidance? The platform links straight to the HeartBeam earnings report filing analysis inside each 10-Q.
Different filings answer different investor questions: the HeartBeam annual report 10-K simplified shows long-term strategy and cash runway; an 8-K material events explained notice can reveal pivotal FDA feedback; the HeartBeam proxy statement executive compensation outlines how leadership is rewarded for device milestones. Our coverage spans everything鈥�10-K, 10-Q, 8-K, S-1, Section 16 forms鈥攑aired with expert commentary that highlights clinical trial updates, patent developments, and mHealth market positioning.
Whether you鈥檙e monitoring HeartBeam insider trading Form 4 transactions before key 8-K releases or comparing trial expenses across quarters, Stock Titan鈥檚 AI turns dense disclosures into clear action points. Stop scrolling through hundreds of pages; start focusing on what moves the stock.
HeartBeam, Inc. reported total assets of $5.98 million and combined cash and short-term investments of approximately $5.1 million as of June 30, 2025, with cash and equivalents of $3.26 million. The company recorded a net loss of $4.97 million for the quarter and $10.46 million for the six months ended June 30, 2025, and had an accumulated deficit of $66.73 million. Stockholders' equity was $4.18 million and shares outstanding increased to 34.02 million by June 30, 2025.
R&D expense rose year-to-date as product development and headcount increased while G&A declined. The company completed a February public offering that produced approximately $11.5 million in gross proceeds (about $10.3 million net) and issued shares under an ATM, leaving roughly $15.6 million available under that program. The HeartBeam System received FDA clearance on December 13, 2024; the company filed a 510(k) for its 12-lead synthesis software in January 2025, and its VALID-ECG pivotal study showed 93.4% diagnostic agreement. Management discloses substantial doubt about the company鈥檚 ability to continue as a going concern absent additional financing.
FAQ
What is the current stock price of Heartbeam (BEAT)?
What is the market cap of Heartbeam (BEAT)?
